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Background:  Implantable intra-thoracic impedance device has shown that lung fluid accumulation in patients with decompensated chronic heart 
failure (CHF) begins several days before admission, but predicts hospitalizations with only 50-76% accuracy.
Aim: We evaluated the ability of a non-invasive impedance device to predict decompensation in CHF patients and to trigger early therapy in order to 
prevent hospitalizations. 
Methods:  Lung impedance (LI) was measured by a new non-invasive technique. Changes in the clinical status of patients, LI and NT-proBNP levels 
were concurrently recorded at each outpatient heart failure clinic visit (23±19 days).
Results:  147 CHF patients (72±10 years, LVEF=24±6%) at NYHA II/III/IV (62/57/28) were followed for 28±13 months in an outpatient clinic. 
Patients were treated with diuretics, beta blockers and ACE/ARB/aldosterone. An LI decrease>15% from normal baseline was used to initiate early 
preventive therapy since we have shown previously that clinical decompensation occurred at this level of LI decrease. 73 of 147 patients were 
treated by clinical evaluation (Group1) and 74 according to LI (Group 2). LVEF and NT-proBNP in groups 1 and 2 were 24±7%, 5730±2584 pg/
ml, and 24±6% and 5821±2674 pg/ml, respectively (p=NS). 134 episodes of LI decrease>15% occurred in group 1 with treatment administered 
according to clinical signs only. These LI decrease episodes included 118 hospitalizations and 33 deaths. Positive predictive value for hospitalization 
at level of LI decrease>15% was 88%. In group 2, 143 episodes of LI decrease>15% were recorded. Treatment was immediately intensified. 
In 114 cases LI increased as the result of treatment intensification and only 29 hospitalizations were required (p<0.01) and 10 patients died 
(p<0.01). LI decrease at admission in group 2 (27±5.5%) was similar to that in group 1 (26±5.4%). Time elapsed between LI decrease > 15% and 
hospitalization in both groups was 16±6 days.
Conclusions:  Lung impedance monitoring of CHF patients in an outpatient clinic to predict decompensation and admission is feasible. Preventive 
early LI-guided treatment is effective and may prevent hospitalizations and deaths. 
